India's New Drug and Clinical Trial Rules Are Reshaping Regulatory Hiring for Global Sponsors

Introduction

For a long time, global sponsors treated India largely as a late addition to a clinical development or launch plan, a market to file in once the core submissions elsewhere were already settled. That calculus has shifted. India's New Drugs and Clinical Trials Rules, which took effect in 2019 and overhauled procedures that had been built up piecemeal under the country's decades-old Drugs and Cosmetics Act, changed both the speed and the structure of how the Central Drugs Standard Control Organisation reviews trials and new drug applications. Combined with government incentives pulling pharmaceutical manufacturing toward India, the practical effect has been a steady rise in demand for regulatory affairs professionals who understand how the Indian system actually works, rather than treating it as a generic emerging-market filing.

This matters for two different groups of regulatory professionals: those based in India building careers inside the country's growing pharmaceutical and biotech sector, and those at multinational sponsors elsewhere who increasingly need to plan India into a global submission strategy from the start rather than as an afterthought.

The New Drugs and Clinical Trials Rules, 2019: What Changed

Before 2019, India's clinical trial approval process was governed by provisions that had been amended repeatedly over the years, creating a patchwork that sponsors and even domestic regulatory professionals found difficult to navigate consistently. The 2019 rules replaced that patchwork with a single, more structured framework administered by the Central Drugs Standard Control Organisation under the Drugs Controller General of India, covering clinical trial approval, ethics committee registration and oversight, and the process for bringing a new drug to market in India.

A central feature of the overhaul was defined review timelines tied to specific application types, replacing a process that previously had no hard statutory clock in many cases. The rules also formalized requirements around ethics committee registration with the regulator, strengthening oversight of the bodies responsible for protecting trial participants at the site level, and set out a clearer compensation framework for clinical trial-related injury or death, an area that had drawn significant scrutiny in India in the years leading up to the reform.

Faster Timelines, With a Catch

The rules introduced defined timeframes for the regulator to respond to clinical trial applications, with a deemed approval provision if the authority does not communicate a decision within the specified period. For sponsors used to waiting indefinitely for a decision from the Indian authority, this was a meaningful structural change, since it created a statutory backstop rather than leaving timing entirely at the regulator's discretion.

Regulatory professionals working on India filings should treat the deemed approval mechanism as a useful backstop rather than the primary plan. In practice, incomplete or poorly prepared applications routinely draw queries that restart the clock, and a deemed approval that later surfaces a quality gap in the application is not a position any sponsor wants to be in once a trial is underway. Experienced India-focused regulatory professionals build their submission timelines around getting a complete, query-free application in on the first attempt, treating the statutory clock as a ceiling rather than a target.

The Waiver Pathway for Globally Approved Drugs

One of the more consequential provisions for multinational sponsors is a waiver mechanism that allows, under defined circumstances, a local clinical trial requirement in India to be waived for a drug already approved and marketed in certain other countries, most relevant for situations such as drugs for rare diseases, drugs addressing an unmet medical need, or drugs needed in a public health emergency. Where it applies, this waiver can meaningfully shorten the path to approval in India compared with running a separate local trial from scratch.

The waiver is not automatic, and the criteria for when it applies require careful regulatory judgment rather than a simple checklist. Sponsors still need to build a case for why the existing data adequately represents expected outcomes in the Indian population, and regulatory professionals who can assess that question credibly, rather than simply asserting it, are doing some of the more strategically valuable work in this space.

Local Manufacturing Incentives Are Adding Pressure

Separate from the clinical trial and marketing authorization reforms, India's production-linked incentive programs aimed at pharmaceutical manufacturing have encouraged both domestic and multinational companies to expand manufacturing footprint inside the country. That expansion creates its own regulatory workload, since manufacturing sites feeding both domestic and export markets need to satisfy India's quality and licensing requirements alongside whatever standards apply in the destination markets, and companies building or expanding Indian manufacturing need regulatory professionals who can manage that dual compliance picture.

The combination of faster clinical trial review, a workable waiver pathway for certain globally approved drugs, and manufacturing incentives pulling more production into the country has made India a market that regulatory leadership increasingly wants represented at the planning table earlier in a program's lifecycle, not brought in only once a filing is imminent.

What This Means for Regulatory Hiring in India and Abroad

Inside India, the more structured and faster-moving framework has raised the bar for what regulatory affairs teams at domestic pharmaceutical and biotech companies are expected to deliver, since a defined statutory timeline only helps a sponsor if the team preparing the submission can actually hit it with a complete application. This has increased demand for regulatory professionals with strong command of CDSCO procedure and ethics committee requirements, not just general familiarity with the Drugs and Cosmetics Act.

At multinational sponsors headquartered elsewhere, the hiring signal looks different: companies increasingly want a regulatory lead, whether an in-country hire, a dedicated India specialist on a global team, or a well-vetted local consulting partner, who can advise early on whether a program qualifies for the waiver pathway, what a realistic India timeline actually looks like given the first-cycle-quality caveat above, and how manufacturing site plans intersect with India's licensing requirements.

Skills and Experience Employers Are Looking For

For regulatory professionals building a career around this market, direct hands-on experience preparing applications under the 2019 rules, including at least one cycle involving a query response, is the clearest differentiator, since it demonstrates familiarity with how CDSCO review actually behaves in practice rather than how the rules read on paper. Experience assessing whether a program meets the criteria for the local trial waiver, even in an analyst or supporting capacity, is valuable because that judgment call sits at the center of a lot of sponsor decision-making about India strategy.

For professionals outside India who want to build credibility advising on this market, developing a working relationship with experienced in-country regulatory counterparts, and being honest about the limits of knowledge gained secondhand rather than from direct filing experience, tends to earn more trust from global regulatory leadership than overstating familiarity with a system that rewards precise, current knowledge.

Language and documentation fluency also matters more than it might seem from outside the market. Correspondence with CDSCO, ethics committee submissions, and the supporting documentation package all need to meet specific formatting and content expectations that differ in meaningful ways from a US or EU submission, and professionals who have only worked with India filings secondhand, through a local partner, often underestimate how much of the actual review friction comes from documentation gaps rather than scientific disagreement. Building real comfort with those formatting and procedural expectations, not just the high-level policy framework, is part of what separates a credible India-focused regulatory hire from one who only knows the rules in outline.

Planning India Into a Global Submission Sequence

One of the more practical shifts prompted by the 2019 framework is where India sits in a sponsor's global submission sequence. Under the old, less predictable system, many multinational sponsors defaulted to filing in India well after their core markets, partly because an unpredictable timeline made it hard to plan India alongside anything else. With defined statutory response windows now in place, some sponsors have started sequencing India earlier, particularly for programs that may qualify for the local trial waiver, since confirming waiver eligibility early can materially change how a global clinical development plan is structured rather than treating India purely as a post-approval market entry exercise.

This earlier sequencing places more weight on regulatory professionals who can give sponsor leadership a realistic read on India timing at the point a global development plan is first being built, not months later once other markets are already locked in. Getting that early read wrong in either direction, assuming the waiver will apply when it will not, or assuming a local trial is required when a waiver case could be made, is a costly planning mistake that experienced India regulatory leads are specifically hired to prevent.

Conclusion

India's 2019 overhaul did not turn the country into a fast, simple filing market, and professionals who treat the deemed approval provision as a guarantee rather than a backstop learn that the hard way. What it did do is give the market a clearer, more predictable structure than it had before, at the same time that manufacturing incentives are pulling more production into the country. For regulatory professionals willing to build real depth in how CDSCO review actually works, that combination has turned India from a late addition to many global plans into a market worth understanding early.